et al., The New England Journal of Medicine , 2023, 10.1056/NEJMoa2301972 Study Objective To evaluate the efficacy, safety, and dose-response effect of Retatrutide a triple GIP, GLP-1, and glucagon receptor agonist in adults with overweight and obesity
This allows you to escalate safely without financial barriers to treatment optimization
It goes back to the effects that the GLP-1 medications have on appetite control
- Muscle loss is a real issue too, as these drugs can hit lean mass hard
These typically include mild redness, itching, or slight discomfort at the injection location
Store the reconstituted vial refrigerated at **28C, protected from light, and use within 28 days**